Furthermore a study by Leverson et al shows that in rodents higher concentrations of Bcl-xl inhibitors in combination with docetaxel can be administered before thrombocytopenia becomes dose limiting, in comparison with combination therapy using ABT-263, in which, because of Bcl-2 inhibition, suppression of granulopoiesis and neutropenia becomes dose limiting at much lower concentrations20. The gene discussed is BCL2L1; the disease is Thrombocytopenia.